Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 24;25:700–710. doi: 10.12659/MSM.911579

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Med Sci Monit, 2019

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

PMC Copyright notice

The effects of treatment with zoledronic acid (ZA) and epidermal growth factor (EGF) on angiogenesis of human umbilical vein endothelial cells (HUVECs) were measured using an assay for the formation of vascular tubes. (A) Human umbilical vein endothelial cells (HUVECs) were treated with Dulbecco’s modified Eagle’s medium (DMEM) without zoledronic acid or epidermal growth factor (EGF) for 48 h. (B) HUVECs were treated with 5 μmol/L of zoledronic acid for 48 h. (C) HUVECs were treated with 10 ng/L of EGF for 48 h. (D) HUVECs were treated with 5 μmol/L of zoledronic acid and 10 ng/L EGF for 48 h. Results are presented as the average ±SD of three independent experiments. (E) a: Zoledronic acid significantly inhibited angiogenesis at a concentration of 5 μmol/L (P<0.05). b: EGF treatment could partially reverse the negative effects of zoledronic acid (P<0.05).